| The prevention of cytomegalovirus disease in renal transplantation. | |
| | |
MedLine Citation:
|
PMID: 1698020 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Primary cytomegalovirus (CMV) disease can be prevented in renal transplant recipients with the use of either CMV hyperimmune globulin (CMVIg) or acyclovir. Started within 72 hours of transplantation and continued for 16 weeks posttransplant, CMVIg decreases the incidence of primary CMV disease from 60% to 21%. Acyclovir administered preoperatively and for 3 months thereafter decreases the incidence of CMV disease from 29% to 8% and is the most cost-effective therapy. The effectiveness of these preparations in preventing CMV reinfection or reactivation has not been established. The utility of therapies other than CMVIg or acyclovir for the prevention of CMV disease has not been proven; CMV vaccination is ineffective, polyvalent immunoglobulins require further study, and interferon alpha (IFN-alpha) has been associated with frequent irreversible rejection reactions and therefore should not be used for CMV prophylaxis. Although further investigation is necessary, patients at risk for primary CMV disease should receive prophylactic therapy with either CMVIg or acyclovir. |
| | |
Authors:
|
C L Davis |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of kidney diseases : the official journal of the National Kidney Foundation Volume: 16 ISSN: 0272-6386 ISO Abbreviation: Am. J. Kidney Dis. Publication Date: 1990 Sep |
Date Detail:
|
Created Date: 1990-10-17 Completed Date: 1990-10-17 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8110075 Medline TA: Am J Kidney Dis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 175-88 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Virginia Mason Clinic, Seattle, WA 98111. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antiviral Agents
/
therapeutic use Cytomegalovirus Infections / etiology, prevention & control* Humans Immunization, Passive Interferons / therapeutic use Kidney Transplantation / adverse effects* Opportunistic Infections / prevention & control Vaccination |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 9008-11-1/Interferons |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lack of response of bone marrow, in vitro, to growth factors in congenital neutropenia.
Next Document: The effect of mouth closure on drooling and speech.